211 related articles for article (PubMed ID: 38650924)
41. Breast cancer susceptibility gene 1 regulates oxidative damage via nuclear factor erythroid 2-related factor 2 in oral cancer cells.
Yu X; Liu Y; Pan K; Sun P; Li J; Li L; Chen Q; Sun Z
Arch Oral Biol; 2022 Jul; 139():105447. PubMed ID: 35512617
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer.
Ouyang S; Li H; Lou L; Huang Q; Zhang Z; Mo J; Li M; Lu J; Zhu K; Chu Y; Ding W; Zhu J; Lin Z; Zhong L; Wang J; Yue P; Turkson J; Liu P; Wang Y; Zhang X
Redox Biol; 2022 Jun; 52():102317. PubMed ID: 35483272
[TBL] [Abstract][Full Text] [Related]
43. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
44. M1 macrophage-derived exosomes and their key molecule lncRNA HOTTIP suppress head and neck squamous cell carcinoma progression by upregulating the TLR5/NF-κB pathway.
Jiang H; Zhou L; Shen N; Ning X; Wu D; Jiang K; Huang X
Cell Death Dis; 2022 Feb; 13(2):183. PubMed ID: 35210436
[TBL] [Abstract][Full Text] [Related]
45. Targeting polarized phenotype of microglia via IL6/JAK2/STAT3 signaling to reduce NSCLC brain metastasis.
Jin Y; Kang Y; Wang M; Wu B; Su B; Yin H; Tang Y; Li Q; Wei W; Mei Q; Hu G; Lukacs-Kornek V; Li J; Wu K; Yuan X; Wang W
Signal Transduct Target Ther; 2022 Feb; 7(1):52. PubMed ID: 35194016
[TBL] [Abstract][Full Text] [Related]
46. CCR2
Xu H; Zhang S; Sathe AA; Jin Z; Guan J; Sun W; Xing C; Zhang H; Yan B
Front Immunol; 2022; 13():835986. PubMed ID: 35185928
[TBL] [Abstract][Full Text] [Related]
47. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies.
Kumari N; Choi SH
J Exp Clin Cancer Res; 2022 Feb; 41(1):68. PubMed ID: 35183252
[TBL] [Abstract][Full Text] [Related]
48. CAR-macrophage: An extensive immune enhancer to fight cancer.
Wang S; Yang Y; Ma P; Zha Y; Zhang J; Lei A; Li N
EBioMedicine; 2022 Feb; 76():103873. PubMed ID: 35152151
[No Abstract] [Full Text] [Related]
49. NRF2: KEAPing Tumors Protected.
Pillai R; Hayashi M; Zavitsanou AM; Papagiannakopoulos T
Cancer Discov; 2022 Mar; 12(3):625-643. PubMed ID: 35101864
[TBL] [Abstract][Full Text] [Related]
50. Targeting macrophage-mediated tumor cell phagocytosis: An overview of phagocytosis checkpoints blockade, nanomedicine intervention, and engineered CAR-macrophage therapy.
Moradinasab S; Pourbagheri-Sigaroodi A; Ghaffari SH; Bashash D
Int Immunopharmacol; 2022 Feb; 103():108499. PubMed ID: 34972068
[TBL] [Abstract][Full Text] [Related]
51. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei L; Ren X; Yu H; Zhan Y
Front Immunol; 2021; 12():771210. PubMed ID: 34804061
[TBL] [Abstract][Full Text] [Related]
52. Nrf2/Keap1/ARE signaling: Towards specific regulation.
Ulasov AV; Rosenkranz AA; Georgiev GP; Sobolev AS
Life Sci; 2022 Feb; 291():120111. PubMed ID: 34732330
[TBL] [Abstract][Full Text] [Related]
53. Combination strategies to maximize the benefits of cancer immunotherapy.
Zhu S; Zhang T; Zheng L; Liu H; Song W; Liu D; Li Z; Pan CX
J Hematol Oncol; 2021 Sep; 14(1):156. PubMed ID: 34579759
[TBL] [Abstract][Full Text] [Related]
54. Head and neck cancer.
Mody MD; Rocco JW; Yom SS; Haddad RI; Saba NF
Lancet; 2021 Dec; 398(10318):2289-2299. PubMed ID: 34562395
[TBL] [Abstract][Full Text] [Related]
55. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
[TBL] [Abstract][Full Text] [Related]
56. Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy.
Kang M; Lee SH; Kwon M; Byun J; Kim D; Kim C; Koo S; Kwon SP; Moon S; Jung M; Hong J; Go S; Song SY; Choi JH; Hyeon T; Oh YK; Park HH; Kim BS
Adv Mater; 2021 Oct; 33(43):e2103258. PubMed ID: 34510559
[TBL] [Abstract][Full Text] [Related]
57. Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.
Xu M; Wang Y; Xia R; Wei Y; Wei X
Cell Prolif; 2021 Oct; 54(10):e13115. PubMed ID: 34464477
[TBL] [Abstract][Full Text] [Related]
58. Recent advancement on development of drug-induced macrophage polarization in control of human diseases.
Wang L; Lu Q; Gao W; Yu S
Life Sci; 2021 Nov; 284():119914. PubMed ID: 34453949
[TBL] [Abstract][Full Text] [Related]
59. Cigarette smoke promotes oral leukoplakia via regulating glutamine metabolism and M2 polarization of macrophage.
Zhu Y; Zhang S; Sun J; Wang T; Liu Q; Wu G; Qian Y; Yang W; Wang Y; Wang W
Int J Oral Sci; 2021 Aug; 13(1):25. PubMed ID: 34373444
[TBL] [Abstract][Full Text] [Related]
60. Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor-Glioma Therapy?
Tong N; He Z; Ma Y; Wang Z; Huang Z; Cao H; Xu L; Zou Y; Wang W; Yi C; Yin Z; Wang Q
Front Cell Dev Biol; 2021; 9():706286. PubMed ID: 34368156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
